Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rincon Pharmaceuticals Inc.

Latest From Rincon Pharmaceuticals Inc.

The Next-Generation Antibody Players

A host of companies are vying to develop new and improved antibodies. Technologies span the gamut from improving ADCC effector function to stripping away components of traditional antibodies to create leaner molecules that may be cheaper to manufacture and eaiser to deliver orally. These start-ups remain product focused, eschewing the platform technology model. Pharmaceutical and established biotechnology companies are eager to get their hands on the technologies, causing a flurry of deal-making in the last year.
BioPharmaceutical Strategy

Selected Start-Ups (6/05)

In Vivo briefly summarizes the technologies of these recently founded companies: Biomarker Technologies, Flexicath, OncoVista, Rincon Pharmaceuticals, ThermopeutiX and ZooBiotic.

Emergings in Brief (6/05)

Start-Up showcases these recently launched companies: Flexicath, Glenveigh Pharmaceuticals, Rincon Pharmaceuticals and Ryogen.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rincon Pharmaceuticals Inc.
  • Senior Management
  • Bruce Steel, CEO
    Peter B Heifetz, PhD, CSO
  • Contact Info
  • Rincon Pharmaceuticals Inc.
    Phone: (858) 754-3035
    505 Coast Blvd. S.
    Ste. 412
    La Jolla, CA 92037